Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000041

Senior Vice President, Finance sold 10,290 shares at an average $59.07 ($607,806)

  • Senior Vice President, Finance acquired 7,833 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Agarwal Arjun · Senior Vice President, Finance

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-05-18 Exercise or conversion : show line 1 in the form 10b5-1 +2,000 $12.50 $25,000 20,863 D
2026-05-18 Exercise or conversion : show line 2 in the form 10b5-1 +5,833 $34.39 $200,597 26,696 D
2026-05-18 Sale : show line 3 in the form 10b5-1 −4,190 $58.34 $244,465 22,506 D
2026-05-18 Sale : show line 4 in the form 10b5-1 −4,600 $59.19 $272,260 17,906 D
2026-05-18 Sale : show line 5 in the form 10b5-1 −800 $60.34 $48,269 17,106 D
2026-05-18 Sale : show line 6 in the form 10b5-1 −700 $61.16 $42,812 16,406 D
Open-market sales · 10,290 sh · avg $59.07 · $607,806

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-05-18 Exercise or conversion : show line 7 in the form 10b5-1 Employee Stock Option (right to buy) −2,000 118,000 D
2026-05-18 Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (right to buy) −5,833 64,167 D
Loading xslF345X06/form4.xml…